{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:59:26Z","timestamp":1790812766452,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cardiac magnetic resonance (CMR) with parametric mapping can improve the characterization of myocardial tissue. We studied the diagnostic value of native T1 mapping to detect cardiac amyloidosis in patients with left ventricular (LV) hypertrophy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred twenty-five patients with increased LV wall thickness (\u2265\u200912\u00a0mm end-diastole) who received clinical CMR in a 3\u00a0T scanner between 2017 and 2020 were included. 31 subjects without structural heart disease served as controls. Native T1 was measured as global mean value from 3 LV short axis slices. The study was registered at German clinical trial registry (DRKS00022048).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean age of the patients was 66\u2009\u00b1\u200914\u00a0years, 83% were males. CA was present in 24 patients, 21 patients had hypertrophic cardiomyopathy (HCM), 80 patients suffered from hypertensive heart disease (HHD). Native T1 times were higher in patients with CA (1409\u2009\u00b1\u200959\u00a0ms, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) compared to healthy controls (1225\u2009\u00b1\u200921\u00a0ms), HCM (1266\u2009\u00b1\u200944\u00a0ms) and HHD (1257\u2009\u00b1\u200941\u00a0ms). HCM and HHD patients did not differ in their native T1 times but were increased compared to control (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). ROC analysis of native T1 demonstrated an area under the curve for the detection of CA vs. HCM and HHD of 0.9938 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), which was higher than that of extracellular volume (0.9876) or quantitative late gadolinium enhancement (0.9406; both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). The optimal cut-off value of native T1 to diagnose CA was 1341\u00a0ms (sensitivity 100%, specificity 97%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Non-contrast CMR imaging with native T1 mapping provides high diagnostic accuracy to diagnose cardiac amyloidosis in patients with left ventricular hypertrophy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00392-022-02005-2","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T02:03:37Z","timestamp":1648692217000},"page":"334-342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7932-212X","authenticated-orcid":false,"given":"Daniel","family":"Lavall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola H.","family":"Vosshage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romy","family":"Ge\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"St\u00f6be","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm","family":"Denecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hagendorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Laufs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"2005_CR1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","author":"MS Maurer","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T et al (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Hear Fail. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006075","journal-title":"Circ Hear Fail"},{"key":"2005_CR2","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV et al (2020) Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association. Circulation 142:e7\u2013e22. https:\/\/doi.org\/10.1161\/CIR.0000000000000792","journal-title":"Circulation"},{"key":"2005_CR3","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M et al (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:2872\u20132891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","journal-title":"J Am Coll Cardiol"},{"key":"2005_CR4","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","journal-title":"Circulation"},{"key":"2005_CR5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110:479\u2013506. https:\/\/doi.org\/10.1007\/s00392-020-01799-3","journal-title":"Clin Res Cardiol"},{"key":"2005_CR6","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"PM Elliott","year":"2014","unstructured":"Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733\u20132779. https:\/\/doi.org\/10.1093\/eurheartj\/ehu284","journal-title":"Eur Heart J"},{"key":"2005_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/eurheartj\/ehi258","volume":"26","author":"H Mahrholdt","year":"2005","unstructured":"Mahrholdt H, Wagner A, Judd RM et al (2005) Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26:1461\u20131474. https:\/\/doi.org\/10.1093\/eurheartj\/ehi258","journal-title":"Eur Heart J"},{"key":"2005_CR8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijcard.2017.10.094","volume":"254","author":"AN Ganesan","year":"2018","unstructured":"Ganesan AN, Gunton J, Nucifora G et al (2018) Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 254:230\u2013237. https:\/\/doi.org\/10.1016\/j.ijcard.2017.10.094","journal-title":"Int J Cardiol"},{"key":"2005_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"DR Messroghli","year":"2017","unstructured":"Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin. J Cardiovasc Magn Reson 19:75. https:\/\/doi.org\/10.1186\/s12968-017-0389-8","journal-title":"J Cardiovasc Magn Reson"},{"key":"2005_CR10","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.jcmg.2019.06.023","volume":"12","author":"M Fontana","year":"2019","unstructured":"Fontana M, \u0106orovi\u0107 A, Scully P, Moon JC (2019) Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging 12:2345\u20132356. https:\/\/doi.org\/10.1016\/j.jcmg.2019.06.023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jcmg.2019.03.026","volume":"13","author":"A Baggiano","year":"2020","unstructured":"Baggiano A, Boldrini M, Martinez-Naharro A et al (2020) Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13:69\u201380. https:\/\/doi.org\/10.1016\/j.jcmg.2019.03.026","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jacc.2008.08.064","volume":"53","author":"A Rudolph","year":"2009","unstructured":"Rudolph A, Abdel-Aty H, Bohl S et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. Relation to remodeling. J Am Coll Cardiol 53:284\u2013291. https:\/\/doi.org\/10.1016\/j.jacc.2008.08.064","journal-title":"J Am Coll Cardiol"},{"key":"2005_CR13","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42:1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"2005_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger J, Bluemke DA, Bremerich J et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance\u20142020 update. J Cardiovasc Magn Reson 22:19. https:\/\/doi.org\/10.1186\/s12968-020-00610-6","journal-title":"J Cardiovasc Magn Reson"},{"key":"2005_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12968-019-0595-7","volume":"22","author":"R Kranzusch","year":"2020","unstructured":"Kranzusch R, Aus Dem Siepen F, Wiesemann S et al (2020) Z-score mapping for standardized analysis and reporting of cardiovascular magnetic resonance modified look-locker inversion recovery (MOLLI) T1 data: normal behavior and validation in patients with amyloidosis. J Cardiovasc Magn Reson 22:6. https:\/\/doi.org\/10.1186\/s12968-019-0595-7","journal-title":"J Cardiovasc Magn Reson"},{"key":"2005_CR16","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"2005_CR17","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00392-020-01771-1","volume":"110","author":"G Chatzantonis","year":"2021","unstructured":"Chatzantonis G, Bietenbeck M, Elsanhoury A et al (2021) Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 110:555\u2013568. https:\/\/doi.org\/10.1007\/s00392-020-01771-1","journal-title":"Clin Res Cardiol"},{"key":"2005_CR18","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.jcmg.2017.08.005","volume":"10","author":"AR Patel","year":"2017","unstructured":"Patel AR, Kramer CM (2017) Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging 10:1180\u20131193. https:\/\/doi.org\/10.1016\/j.jcmg.2017.08.005","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003285","author":"R Hinojar","year":"2015","unstructured":"Hinojar R, Varma N, Child N et al (2015) T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. https:\/\/doi.org\/10.1161\/CIRCIMAGING.115.003285","journal-title":"Circ Cardiovasc Imaging"},{"key":"2005_CR20","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro A, Kotecha T, Norrington K et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12:810\u2013819. https:\/\/doi.org\/10.1016\/j.jcmg.2018.02.006","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR21","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.jcmg.2020.03.010","volume":"13","author":"JA Pan","year":"2020","unstructured":"Pan JA, Kerwin MJ, Salerno M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 13:1299\u20131310. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.010","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR22","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/jmri.25885","volume":"47","author":"M van den Boomen","year":"2018","unstructured":"van den Boomen M, Slart RHJA, Hulleman EV et al (2018) Native T1 reference values for nonischemic cardiomyopathies and populations with increased cardiovascular risk: a systematic review and meta-analysis. J Magn Reson Imaging 47:891\u2013912. https:\/\/doi.org\/10.1002\/jmri.25885","journal-title":"J Magn Reson Imaging"},{"key":"2005_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/ehjci\/jeaa063","volume":"21","author":"R Jurcu\u0163","year":"2020","unstructured":"Jurcu\u0163 R, Onciul S, Adam R et al (2020) Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging 21:833\u2013844. https:\/\/doi.org\/10.1093\/ehjci\/jeaa063","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2005_CR24","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","volume":"13","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Cuddy S, Falk RH (2019) How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 13:1368\u20131383. https:\/\/doi.org\/10.1016\/j.jcmg.2019.07.015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcmg.2013.10.008","volume":"7","author":"M Fontana","year":"2014","unstructured":"Fontana M, Banypersad SM, Treibel TA et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7:157\u2013165. https:\/\/doi.org\/10.1016\/j.jcmg.2013.10.008","journal-title":"JACC Cardiovasc Imaging"},{"key":"2005_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.jcmg.2019.06.031","volume":"12","author":"AA Robinson","year":"2019","unstructured":"Robinson AA, Chow K, Salerno M (2019) Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging 12:2332\u20132344. https:\/\/doi.org\/10.1016\/j.jcmg.2019.06.031","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-022-02005-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-022-02005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T07:04:30Z","timestamp":1678345470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-022-02005-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["2005"],"URL":"https:\/\/doi.org\/10.1007\/s00392-022-02005-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"assertion":[{"value":"2 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DL received a research grant and advisory board and speaker honoraria from Pfizer. TD received speaker honoraria and travel expenses from Bayer. Other authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}